SEC Filings TLDR

On August 5, 2025, Vinayak S. Doraiswamy, the Chief Scientific Officer of AtriCure, Inc., sold 2,500 shares of the company's common stock at a price of $36.58 per share. Following this transaction, Doraiswamy owns 71,872 shares of AtriCure, Inc. The sale was reported in a Form 4 filing with the SEC. This transaction re...

On July 29, 2025, Stephen H. Shoemaker, a director of 180 Life Sciences Corp., was granted 919,761 non-qualified stock options under the 2025 Supplemental Option Plan. These options, which vest immediately, are not exercisable until the closing of the transactions contemplated by the July 29, 2025, Securities Purchase ...

William Heard, a director of Anterix Inc., received 7,767 shares of common stock as compensation for his service. The shares were granted on August 5, 2025, and are restricted, vesting in full on the earlier of August 5, 2026, or the next annual stockholder meeting. Heard Capital LLC, for which William Heard is the ult...

Mahvash Yazdi, a director of Anterix Inc., reported her stock holdings and compensation in a Form 4 filing with the SEC. Yazdi received 7,767 shares of common stock as restricted stock compensation for her service as a non-employee director. These shares will vest on August 5, 2026, or at the next annual stockholder me...

Leslie B. Daniels, a director of Anterix Inc., received a grant of 7,767 shares of common stock as compensation for his service on the board of directors. The shares are restricted and will vest in full on the earlier of August 5, 2026, or the next annual stockholder meeting, provided the vesting date is a trading day ...

Anterix Inc. (ATEX) reported that Mark Fleischhauer, a non-employee director on the company's board, received 7,767 restricted shares of common stock as compensation for his services. The shares were granted on August 5, 2025, and will vest in full on the earlier of August 5, 2026, or the company's next annual stockhol...

The SEC filing details the stock holdings and transactions of Jeffrey A. Altman, a director and ten percent owner of Anterix Inc. (ATEX). As of August 5, 2025, Altman directly owns 124,492 shares of Common Stock and indirectly owns 5,411,776 shares through Owl Creek Asset Management, L.P. On the same date, Altman was g...

On August 6, 2025, David Sponsel, EVP of Sales at Alphatec Holdings, Inc., filed a Form 4 with the SEC. The filing reports the disposition of 982 shares of common stock at a price of $15.34 per share. The shares were withheld by the issuer to satisfy tax withholding obligations resulting from the vesting of restricted ...

On August 6, 2025, John Todd Koning, the Chief Financial Officer of Alphatec Holdings, Inc., sold 5,315 shares of the company's common stock at a price of $15.34 per share. The shares were withheld by the issuer to satisfy tax withholding obligations resulting from the vesting of restricted stock units. Following this ...

Craig E. Hunsaker, EVP of People & Culture at Alphatec Holdings, Inc., sold shares of the company's common stock on August 5 and August 6, 2025. On August 5, he sold 50,000 shares at a weighted average price of $15.00 to $15.01 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025. On August 6, he ...

Thomas A. Satterfield Jr., a 10% owner of ARK Restaurants Corp. (ARKR), reported several transactions in the company's common stock. On August 5, 2025, Satterfield acquired 25,000 shares through Caldwell Mill Opportunity Fund at a weighted average price of $6.71. On the same day, he acquired 20,916 shares through A.G. ...

On August 5, 2025, Srdjan Tanjga, the Chief Financial Officer of Appian Corp, was granted 235,680 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Appian's Class A Common Stock or its cash equivalent, at the discretion of the company. The RSUs vest in four equal annual insta...

Mohammad Saidal LaVanway, the Chief Financial Officer of Applied Digital Corp., reported several stock transactions on August 5, 2025. These transactions included the vesting of Restricted Stock Units (RSUs) and the withholding of shares for tax purposes. The RSUs, granted on August 5, 2022, vested in multiple tranches...

The SEC filing details the stock transactions and holdings of Wes Cummins, the CEO and Chairman of Applied Digital Corp. (APLD). The filing includes information on restricted stock units (RSUs) granted to Cummins, which vest over a period from February 2023 to August 2025. The RSUs represent a contingent right to recei...

Michael R. Winter, a director of Allient Inc., acquired 597 shares of common stock on August 6, 2025, at a price of $39.79 per share. This acquisition was made pursuant to the company's Non-Employee Director Compensation Policy under the 2017 Omnibus Incentive Plan. Following this transaction, Winter owns a total of 39...

On August 6, 2025, Nicole R. Tzetzo, a director of Allient Inc., reported transactions involving the company's common stock. Tzetzo acquired 597 shares at a price of $39.79 per share, increasing her total holdings to 13,415 shares. This transaction was made pursuant to the company's Non-Employee Director Compensation P...

Steven C. Finch, a director of Allient Inc., acquired 597 shares of common stock on August 6, 2025, at a price of $39.79 per share. This acquisition was made pursuant to the company's Non-Employee Director Compensation Policy under the 2017 Omnibus Incentive Plan. Following this transaction, Finch owns a total of 12,18...

On August 6, 2025, Richard D. Federico, a director of Allient Inc., received 692 shares of common stock as part of the company's Non-Employee Director Compensation Policy under the 2017 Omnibus Incentive Plan. The shares were granted at a price of $39.79 per share. Following this transaction, Federico owns a total of 7...

On August 6, 2025, Robert B. Engel, a director of Allient Inc, acquired 597 shares of common stock at a price of $39.79 per share. This transaction was part of the grant of quarterly retainer shares under the company's Non-Employee Director Compensation Policy, as per the 2017 Omnibus Incentive Plan. Following this tra...

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc., reported several stock transactions on August 5, 2025. These transactions included the exercise of stock options for 12,500 shares at a price of $21.09 per share, resulting in a total of 7,433 shares owned following the transaction. Additionally, Rolp...

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., sold 50,000 shares of common stock on August 5, 2025, at a weighted average price of $13.1199 per share. The transaction was executed under a 10b5-1 trading plan adopted by K. Charles Janac, the manager of Bayview Legacy, LLC, on March 5, 2025. The shares were sold in ...

Antonio J. Viana, a director of Arteris, Inc., sold 6,909 shares of common stock on August 5, 2025, at a weighted average price of $14.1409 per share. The transaction was conducted pursuant to a 10b5-1 trading plan adopted on June 13, 2024. Following the sale, Viana's total ownership in the company stands at 196,461 sh...

On August 5, 2025, S. Atiq Raza, a director of Arteris, Inc., sold 63,118 shares of the company's common stock at a weighted average price of $13.074 per share. The shares were sold pursuant to a 10b5-1 trading plan adopted on June 6, 2024. The sale price ranged from $12.35 to $14.20 per share. Following the transactio...

Laurent R. Moll, the Chief Operating Officer of Arteris, Inc., sold 34,400 shares of common stock on August 5, 2025, under a pre-arranged 10b5-1 trading plan adopted on March 12, 2025. The shares were sold at a weighted average price of $13.5687, with the actual sale prices ranging from $12.90 to $14.20 per share. Foll...

Nicholas B. Hawkins, VP and Chief Financial Officer of Arteris, Inc., sold 11,276 shares of common stock on August 5, 2025, at a weighted average price of $13.1505 per share. The transaction was executed under a 10b5-1 trading plan adopted on May 20, 2024. Following the sale, Hawkins owns 107,996 shares of the company'...